申请人:Novagenesis Foundation
公开号:US20150011458A1
公开(公告)日:2015-01-08
The present invention relates to compounds of Formula I, IA, II, HA, III, or IHA and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds for the selective inhibition of one or more caspases. Also described are methods where the compounds of Formula I, IA, II, IIA, III, or IIIA are used in the prevention and/or treatment of various diseases and conditions in subjects, including caspase-mediated diseases such as sepsis, myocardial infarction, ischemic stroke, spinal cord injury (SCI), traumatic brain injury (TBI) and neurodegenerative disease (e.g. multiple sclerosis (MS) and Alzheimer's, Parkinson's, and Huntington's diseases).
本发明涉及式I、IA、II、IIA、III或IIIA的化合物及其药物用途。本发明的特定方面涉及使用这些化合物对一个或多个半胱氨酸蛋白酶进行选择性抑制的用途。还描述了使用式I、IA、II、IIA、III或IIIA的化合物预防和/或治疗受试者的各种疾病和病况的方法,包括半胱氨酸蛋白酶介导的疾病,如败血症、心肌梗死、缺血性卒中、脊髓损伤(SCI)、创伤性脑损伤(TBI)和神经退行性疾病(例如多发性硬化症(MS)和阿尔茨海默病、帕金森病和亨廷顿病)。